<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2021-2791</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2791</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Рецепторы протеолитических ферментов и адипонектина как потенциальные мишени лекарственной терапии COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Proteolytic enzyme and adiponectin receptors as potential targets for COVID-19 therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7166-7406</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рубина</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rubina</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рубина Ксения Андреевна — доктор биологических наук, доцент кафедры биохимии и молекулярной медицины, заведующая лабораторией морфогенеза и репарации тканей.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><email xlink:type="simple">rkseniya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0570-1880</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сабитова</surname><given-names>Н. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Sabitova</surname><given-names>N. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сабитова Наиля Рашидовна — лаборант-исследователь.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><email xlink:type="simple">inaniel@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0696-1369</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ефименко</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Efimenko</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ефименко Анастасия Юрьевна — кандидат медицинских наук, доцент кафедры биохимии и молекулярной медицины, заведующий лабораторией репарации и регенерации тканей.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><email xlink:type="simple">efimenkoan@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3497-9619</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калинина</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalinina</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калинина Наталья Игоревна — кандидат биологических наук, доцент кафедры биохимии и молекулярной медицины.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><email xlink:type="simple">n_i_kalinina@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0989-7825</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акопян</surname><given-names>Ж. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Akopyan</surname><given-names>J. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Акопян Жанна Алексеевна — кандидат медицинских наук, заведующий кафедрой клинического моделирования и мануальных навыков.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><email xlink:type="simple">zhanna.fbm@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3927-9286</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Semina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семина Екатерина Владимировна — кандидат биологических наук, ведущий научный сотрудник лаборатории молекулярной эндокринологии, старший научный сотрудник НИЛ генных и клеточных технологий по совместительству.</p><p>Москва.</p><p>Тел.: +7 (905) 701-68-72</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><email xlink:type="simple">e-semina@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский государственный университет им. М.В. Ломоносова, Факультет фундаментальной медицины</institution></aff><aff xml:lang="en"><institution>Lomonosov Moscow State University, Faculty of Fundamental Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский государственный университет им. М.В. Ломоносова, Факультет фундаментальной медицины; Московский государственный университет им. М.В. Ломоносова, Институт регенеративной медицины Медицинского научно-образовательного центра</institution></aff><aff xml:lang="en"><institution>Lomonosov Moscow State University, Faculty of Fundamental Medicine; Lomonosov Moscow State University, Institute of Regenerative Medicine, Medical Research and Educational Center</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр кардиологии Минздрава России; Московский государственный университет им. М.В. Ломоносова, Факультет фундаментальной медицины</institution></aff><aff xml:lang="en"><institution>National Medical Research Center of Cardiology; Lomonosov Moscow State University, Faculty of Fundamental Medicine</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>27</day><month>03</month><year>2021</year></pub-date><volume>20</volume><issue>3</issue><fpage>2791</fpage><lpage>2791</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рубина К.А., Сабитова Н.Р., Ефименко А.Ю., Калинина Н.И., Акопян Ж.А., Семина Е.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Рубина К.А., Сабитова Н.Р., Ефименко А.Ю., Калинина Н.И., Акопян Ж.А., Семина Е.В.</copyright-holder><copyright-holder xml:lang="en">Rubina K.A., Sabitova N.R., Efimenko A.Y., Kalinina N.I., Akopyan J.A., Semina E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2791">https://cardiovascular.elpub.ru/jour/article/view/2791</self-uri><abstract><p>Пандемическая ситуация с новой коронавирусной инфекцией COVID-19 (COronaVIrus Disease 2019) требует не только создания вакцин для предотвращения распространения заболевания, но и разработки новых лекарств, направленных на снижение вирусной нагрузки, подавление избыточного иммунного ответа и предотвращение развития тяжелых осложнений, таких как фиброз легких и острый респираторный дистресс-синдром. Одной из перспективных мишеней для изучения механизмов развития пневмонии, системного воспаления и синдрома диссеминированного внутрисосудистого свертывания при COVID-19 является система активаторов плазминогена. У пациентов с тяжелым течением заболевания нарушение активности или экспрессии активаторов плазминогена значительно повышает уровень D-димера и фибриногена в крови, и коррелирует с внутрисосудистым свертыванием и тромбообразованием. Второй перспективной мишенью для изучения патогенеза заболевания при COVID-19 является система адипонектин-Т-кадгерин: адипонектин способен снижать содержание провоспалительных цитокинов, повышение которых характерно при COVID-19, и стимулировать продукцию противовоспалительного цитокина — интерлейкина-10. В обзоре описана роль активаторов плазминогена и Т-кадгерина с точки зрения их возможного участия в развитии фиброза легких при COVID-19, в регуляции системы гемостаза, кардио- и васкуло-протективной функции адипонек-тина и его рецептора — Т-кадгерина.</p></abstract><trans-abstract xml:lang="en"><p>The coronavirus disease 2019 (COVID-19) pandemic requires not only the creation of vaccines to prevent the spread of the disease, but also the development of novel drugs aimed at reducing viral load, suppressing an excessive immune response and preventing the severe complications such as lung fibrosis and acute respiratory distress syndrome. One of the promising targets for studying the development of pneumonia, systemic inflammation and disseminated intravascular coagulation in COVID-19 is the plasminogen activator system. In patients with a severe disease course, impaired activity or expression of plasminogen activators significantly increases the blood level of D-dimer and fibrinogen, as well as correlates with intravascular coagulation and thrombus formation. The second promising target for studying the pathogenesis of COVID-19 is the adiponectin/T-cadherin system: adiponectin is able to reduce the content of pro-inflammatory cytokines, the increase of which is characteristic of COVID-19, and stimulate the production of an anti-inflammatory cytokine interleukin-10. The review describes the role of plasminogen and T-cadherin activators in their possible participation in the development of pulmonary fibrosis in COVID-19 and hemostasis regulation, as well as cardio- and vasculoprotective function of adiponectin and its receptor, T-cadherin.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>система активаторов плазминогена</kwd><kwd>урокиназа uPA</kwd><kwd>рецептор урокиназы uPAR</kwd><kwd>Т-кадгерин</kwd><kwd>адипонектин</kwd><kwd>фиброз легких</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>plasminogen activator system</kwd><kwd>urokinase-type plasminogen activator</kwd><kwd>urokinase-type plasminogen activator receptor</kwd><kwd>T-cadherin</kwd><kwd>adiponectin</kwd><kwd>pulmonary fibrosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Российского фонда фундаментальных исследований (грант РФФИ № 20-04-60029).</funding-statement><funding-statement xml:lang="en">This study was financially supported by the Russian Foundation for Basic Research (grant № 20-04-60029).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. doi:10.1007/s00281-017-0629-x.</mixed-citation><mixed-citation xml:lang="en">Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. doi:10.1007/s00281-017-0629-x.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Guzik TG, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666-87. doi:10.1093/cvr/cvaa106.</mixed-citation><mixed-citation xml:lang="en">Guzik TG, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666-87. doi:10.1093/cvr/cvaa106.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">De Wit E, van Doremalen N, Falzarano, D, Munster V. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34. doi:10.1038/nrmicro.2016.81.</mixed-citation><mixed-citation xml:lang="en">De Wit E, van Doremalen N, Falzarano, D, Munster V. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34. doi:10.1038/nrmicro.2016.81.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Medina-Ennquez M, Lopez-Leon S, Carlos-Escalante J, et al. ACE2: the molecular doorway to SARS-CoV-2. Cell Biosci. 2020;10(148). doi:10.1186/s13578-020-00519-8.</mixed-citation><mixed-citation xml:lang="en">Medina-Ennquez M, Lopez-Leon S, Carlos-Escalante J, et al. ACE2: the molecular doorway to SARS-CoV-2. Cell Biosci. 2020;10(148). doi:10.1186/s13578-020-00519-8.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffmann M, Kleine-Weber Y, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80. e8. doi:10.1016/j.cell.2020.02.052.</mixed-citation><mixed-citation xml:lang="en">Hoffmann M, Kleine-Weber Y, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80. e8. doi:10.1016/j.cell.2020.02.052.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bian H, Zheng ZH, We D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. Medrxiv [Preprint] 2020. Available from: doi:10.1101/2020.03.21.20040691.</mixed-citation><mixed-citation xml:lang="en">Bian H, Zheng ZH, We D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. Medrxiv [Preprint] 2020. Available from: doi:10.1101/2020.03.21.20040691.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. doi:10.1016/S2213-2600(20)30076-X.</mixed-citation><mixed-citation xml:lang="en">Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. doi:10.1016/S2213-2600(20)30076-X.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tang F, Quan Y, Xin ZT, et al. Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study. J Immunol. 2011;186(12):7264-8. doi:10.4049/jimmunol.0903490.</mixed-citation><mixed-citation xml:lang="en">Tang F, Quan Y, Xin ZT, et al. Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study. J Immunol. 2011;186(12):7264-8. doi:10.4049/jimmunol.0903490.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou J, Jin J, Patel E, et al. Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions. Cytokine. 2015;76(2):244-52. doi:10.1016/j.cyto.2015.07.027.</mixed-citation><mixed-citation xml:lang="en">Zhou J, Jin J, Patel E, et al. Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions. Cytokine. 2015;76(2):244-52. doi:10.1016/j.cyto.2015.07.027.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Nakajima W, Sharma K, Lee JY, et al. DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex. Oncotarget. 2016;7(24):36353-65. doi:10.18632/oncotarget.9217.</mixed-citation><mixed-citation xml:lang="en">Nakajima W, Sharma K, Lee JY, et al. DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex. Oncotarget. 2016;7(24):36353-65. doi:10.18632/oncotarget.9217.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi:10.1038/s41586-020-2012-7.</mixed-citation><mixed-citation xml:lang="en">Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. doi:10.1038/s41586-020-2012-7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffmann M, Kleine-Weber H, Pohlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020;78(4):779-84.e5. doi:10.1016/j.molcel.2020.04.022.</mixed-citation><mixed-citation xml:lang="en">Hoffmann M, Kleine-Weber H, Pohlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020;78(4):779-84.e5. doi:10.1016/j.molcel.2020.04.022.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Raum D, Marcus D, Alpe CA, et al. Synthesis of human plasminogen by the liver. Science. 1980;208(4447):1036-7. doi:10.1126/science.6990488.</mixed-citation><mixed-citation xml:lang="en">Raum D, Marcus D, Alpe CA, et al. Synthesis of human plasminogen by the liver. Science. 1980;208(4447):1036-7. doi:10.1126/science.6990488.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol. 2020;92(9):1449-59. doi:10.1002/jmv.25822.</mixed-citation><mixed-citation xml:lang="en">Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol. 2020;92(9):1449-59. doi:10.1002/jmv.25822.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Williams FMK, Freydin M, Mangino M, et al. Clinical and molecular characterization of COVID-19 hospitalized patients. medRxiv [Preprint] 2020. doi:10.1101/2020.05.22.20108845.</mixed-citation><mixed-citation xml:lang="en">Williams FMK, Freydin M, Mangino M, et al. Clinical and molecular characterization of COVID-19 hospitalized patients. medRxiv [Preprint] 2020. doi:10.1101/2020.05.22.20108845.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schuliga M, Grainge C, Westall G, et al. The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. Int J Biochem Cell Biol. 2018;97:108-17. doi:10.1016/j.biocel.2018.02.016.</mixed-citation><mixed-citation xml:lang="en">Schuliga M, Grainge C, Westall G, et al. The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. Int J Biochem Cell Biol. 2018;97:108-17. doi:10.1016/j.biocel.2018.02.016.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ji HL, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol Rev. 2020;100(3):1065-75. doi:10.1152/physrev.00013.2020.</mixed-citation><mixed-citation xml:lang="en">Ji HL, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol Rev. 2020;100(3):1065-75. doi:10.1152/physrev.00013.2020.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tkachuk V, Plekhanova O, Beloglazova I, Parfenova E. Role of multidomain structure of urokinase in regulation of growth and remodeling of vessels. Ukr Biochem. J. 2013;85(6):18-45. doi:10.15407/ubj85.06.018.</mixed-citation><mixed-citation xml:lang="en">Tkachuk V, Plekhanova O, Beloglazova I, Parfenova E. Role of multidomain structure of urokinase in regulation of growth and remodeling of vessels. Ukr Biochem. J. 2013;85(6):18-45. doi:10.15407/ubj85.06.018.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачук В. А., Парфенова Е.В., Плеханова О.С. и др. Фибринолитики: от разрушения тромбов до процессов роста и ремоделирования сосудов, нейрогенеза, канцерогенеза и фиброза. Терапевтический архив. 2019;91(9):4-9. doi:10.26442/00403660.2019.09.000411.</mixed-citation><mixed-citation xml:lang="en">Tkachuk VA, Parfyonova YeV, Plekhanova OS, et al. Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis. Terapevticheskii arkhiv. 2019;91(9):4-9. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Semina EV, Rubina KA, Shmakova AA, et al. Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma. J Cell Physiol. 2020;235(9):6268-86. doi:10.1002/jcp.29555.</mixed-citation><mixed-citation xml:lang="en">Semina EV, Rubina KA, Shmakova AA, et al. Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma. J Cell Physiol. 2020;235(9):6268-86. doi:10.1002/jcp.29555.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Климович П. С., Семина Е. В. Механизмы участия урокиназного рецептора в направленном росте аксонов. Молекулярная биология. 2020;54(1):103-13. doi:10.31857/S0026898420010097.</mixed-citation><mixed-citation xml:lang="en">Klimovich PS, Semina EV. Mechanisms of Participation of the Urokinase Receptor in Directed Axonal Growth. Molecular Biology. 2020;54(1):103-13. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Кулебякина М. А., Дыйканов Д. Т., Рубцов Ю. П. и др. Компоненты урокиназной системы оказывают реципрокное влияние на накопление антивоспалитель-ных регуляторных и провоспалительных цитотоксических T-лимфоцитов в селезенке. Иммунология. 2018;39(1):38-43. doi:10.18821/0206-4952-2018-39-1-38-43.</mixed-citation><mixed-citation xml:lang="en">Kulebyakina MA, Dyikanov DT, Rubtsov YP, et al. The components of the urokinase system have a reciprocal effect on the accumulation of anti-inflammatory regulatory and pro-inflammatory cytotoxic T-lymphocytes in the spleen. Immunology. 2018;329(1):38-43. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Swaisgood CM, French EL, Noga C, et al. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol. 2000;157(1):177-87. doi:10.1016/S0002-9440(10)64529-4.</mixed-citation><mixed-citation xml:lang="en">Swaisgood CM, French EL, Noga C, et al. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol. 2000;157(1):177-87. doi:10.1016/S0002-9440(10)64529-4.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Rovina N, Akinosoglou K, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020;24(1):187. doi:10.1186/s13054-020-02897-4.</mixed-citation><mixed-citation xml:lang="en">Rovina N, Akinosoglou K, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020;24(1):187. doi:10.1186/s13054-020-02897-4.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi:10.1016/S0140-6736(20)30937-5.</mixed-citation><mixed-citation xml:lang="en">Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi:10.1016/S0140-6736(20)30937-5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Рубина К.А., Калинина Н. И., Парфенова Е. В., Ткачук В. А. Т-кадгерин как рецептор, участвующий в регуляции ангиогенеза и ремоделировании кровеносных сосудов. Биологические мембраны. 2007;24(1):65-72.</mixed-citation><mixed-citation xml:lang="en">Rubina KA, Kalinina NI, Parfenova EV, Tkachuk VA. T-cadherin as a receptor involved in the regulation of angiogenesis and remodeling of blood vessels. Biologicheskie Membrany. 2007;24(1):65-72. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J, Ren Y, Kang L, et al. Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin. Int J Mol Med. 2014;33:1341-7. doi:10.3892/ijmm.2014.1681.</mixed-citation><mixed-citation xml:lang="en">Liu J, Ren Y, Kang L, et al. Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin. Int J Mol Med. 2014;33:1341-7. doi:10.3892/ijmm.2014.1681.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rubina K, Talovskaya E, Cherenkov V, et al. LDL induces intracellular signalling and cell migration via atypical LDL-binding protein T-cadherin. Mol Cell Biochem. 2005;273(1-2):33-41. doi:10.1007/s11010-005-0250-5.</mixed-citation><mixed-citation xml:lang="en">Rubina K, Talovskaya E, Cherenkov V, et al. LDL induces intracellular signalling and cell migration via atypical LDL-binding protein T-cadherin. Mol Cell Biochem. 2005;273(1-2):33-41. doi:10.1007/s11010-005-0250-5.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Рубина К. А., Ткачук В. А. Молекулярные и клеточные механизмы физиологического и опухолевого роста кровеносных сосудов. Российский физиологический журнал им. И. М. Сеченова. 2017;103(2):121-37.</mixed-citation><mixed-citation xml:lang="en">Rubina KA, Tkachuk VA. Molecular and cellular mechanisms of physiological and tumor growth of blood vessels. Russian Journal of Physiology im. I. M. Sechenova. 2017;2017(2):121-37. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Frismantiene A, Pfaff D, Frachet A, et al. Regulation of contractile signaling and matrix remodeling by T-cadherin in vascular smooth muscle cells: constitutive and insulin-dependent effects. Cell Signal. 2014;26(9):1897-908. doi:10.1016/j.cellsig.2014.05.001.</mixed-citation><mixed-citation xml:lang="en">Frismantiene A, Pfaff D, Frachet A, et al. Regulation of contractile signaling and matrix remodeling by T-cadherin in vascular smooth muscle cells: constitutive and insulin-dependent effects. Cell Signal. 2014;26(9):1897-908. doi:10.1016/j.cellsig.2014.05.001.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Philippova M, Suter Y, Toggweiler S, et al. T-cadherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis. Eur Heart J. 2011;32(6):760-71. doi:10.1093/eurheartj/ehq206.</mixed-citation><mixed-citation xml:lang="en">Philippova M, Suter Y, Toggweiler S, et al. T-cadherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis. Eur Heart J. 2011;32(6):760-71. doi:10.1093/eurheartj/ehq206.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Semina EV, Rubina KA, Sysoeva VY, et al. Novel mechanism regulating endothelial permeability via T-cadherin-dependent VE-cadherin phosphorylation and clathrin-mediated endocytosis. Mol Cell Biochem. 2014;387(1-2):39-53. doi:10.1007/s11010-013-1867-4.</mixed-citation><mixed-citation xml:lang="en">Semina EV, Rubina KA, Sysoeva VY, et al. Novel mechanism regulating endothelial permeability via T-cadherin-dependent VE-cadherin phosphorylation and clathrin-mediated endocytosis. Mol Cell Biochem. 2014;387(1-2):39-53. doi:10.1007/s11010-013-1867-4.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Рубина К. А., Семина Е.В., Балацкая М.Н. и др. Механизмы регуляции направленного роста нервов и сосудов компонентами фибринолитической системы и GPI-заякоренными навигационными рецепторами. Российский физиологический журнал им. И.М. Сеченова. 2018;104(9):1001-26. doi:10.7868/S0869813918090010.</mixed-citation><mixed-citation xml:lang="en">Rubina KA, Semina EV, Balatskaya MN, et al. Mechanisms of regulation of directed growth of nerves and blood vessels by components of the fibrinolytic system and GPI-anchored navigation receptors. Russian Journal of Physiology im. I. M. Sechenova. 2018;104(9):1001-26. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Balatskaya M, Sharonov G, Baglay A, et al. One receptor, two ligands, different responses: T-cadherin as a receptor for low density lipoprotein and adiponectin. FEBS J. 2017;284:153. doi:10.1111/febs.14174.</mixed-citation><mixed-citation xml:lang="en">Balatskaya M, Sharonov G, Baglay A, et al. One receptor, two ligands, different responses: T-cadherin as a receptor for low density lipoprotein and adiponectin. FEBS J. 2017;284:153. doi:10.1111/febs.14174.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Min X, Lemon B, Tang J, et al. Crystal structure of a singlechain trimer of human adiponectin globular domain. FEBS Lett. 2012;586(6):912-7. doi:10.1016/j.febslet.2012.02.024.</mixed-citation><mixed-citation xml:lang="en">Min X, Lemon B, Tang J, et al. Crystal structure of a singlechain trimer of human adiponectin globular domain. FEBS Lett. 2012;586(6):912-7. doi:10.1016/j.febslet.2012.02.024.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Choi H, Doss H, Kim K. Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int J Mol Sci. 2020;21(4):1219. doi:10.3390/ijms21041219.</mixed-citation><mixed-citation xml:lang="en">Choi H, Doss H, Kim K. Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int J Mol Sci. 2020;21(4):1219. doi:10.3390/ijms21041219.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Рубина К. А., Сысоева В. Ю., Семина Е. В. и др. Особенности экспрессии Т-кадгерина в кератиноцитах и сосудах эпителиальных опухолей кожи. Российский журнал кожных и венерических болезней. 2013;2013(1):9-14.</mixed-citation><mixed-citation xml:lang="en">Rubina KA, Sysoeva VYu, Semina EV, et al. Features of T-cadherin expression in keratinocytes and vessels of epithelial skin tumors. Russian Journal of Skin and Venereal Diseases. 2013;2013(1):9-14. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Clark L, Taylor C, Zahradka P. Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor. Endocr. Metab. Immune Disord. Drug Targets. 2017;17(3):200-6. doi:10.2174/1871530317666170818120224.</mixed-citation><mixed-citation xml:lang="en">Clark L, Taylor C, Zahradka P. Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor. Endocr. Metab. Immune Disord. Drug Targets. 2017;17(3):200-6. doi:10.2174/1871530317666170818120224.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Nigro E, Matteis M, Roviezzo F, et al. Role of adiponectin in sphingosine-1-phosphate induced airway hyperresponsiveness and inflammation. Pharmacol Res. 2016;103:114-22. doi:10.1016/j.phrs.2015.10.004.</mixed-citation><mixed-citation xml:lang="en">Nigro E, Matteis M, Roviezzo F, et al. Role of adiponectin in sphingosine-1-phosphate induced airway hyperresponsiveness and inflammation. Pharmacol Res. 2016;103:114-22. doi:10.1016/j.phrs.2015.10.004.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong YH, Peng H, Cheng HZ, Wang P. Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer. Asian Pac J Cancer Prev. 2015;16(3):1139-43. doi:10.7314/apjcp.2015.16.3.1139.</mixed-citation><mixed-citation xml:lang="en">Zhong YH, Peng H, Cheng HZ, Wang P. Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer. Asian Pac J Cancer Prev. 2015;16(3):1139-43. doi:10.7314/apjcp.2015.16.3.1139.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
